Assessment of Viral Shedding Week Following Administration of Live

Status Completed

Clinical Trial Summary

LAIV shedding studies in children could be an important way to confirm whether impediments to viral replication do indeed explain these observed reductions in vaccine effectiveness (VE), whether prior vaccination has any influence on replication and what future implications (if any) this might have for the UK paediatric LAIV programme. LAIV virus replication in children will be dependent on virological and host factors. The virus factors include replicative fitness of individual strains and the susceptibility to inhibition by other replicating strains (ability to compete). Host factors which may influence this include pre-existing specific immunity as a result of prior infection or previous vaccination (with either LAIV or IIV), and innate immune factors including mucosal immunity. There is significant variability in shedding across viral subtypes in studies done to date, so there is a need to obtain local data in a small pilot observational study which will look in detail at virus shedding by sequential daily virus samples, something not possible on a larger scale. The data generated will inform future LAIV studies in the UK in terms of optimum time of sample collection for viral shedding studies, which are likely to be required on a regular basis, to supplement field studies of vaccine effectiveness. This study will enrol up to 30 children that will allow these factors to be assessed. Both written informed consent from parent/ guardian and written assent from the child will be in place prior to any study procedure. All participants will have a baseline assessment of pre--existing influenza immunity (blood test, oral fluid collection and nasal swabs), followed by a single dose of LAIV. Parents will then be asked to take nasal swabs at home on days 1, 2, 3, 4, 5, 6, 7, 8, with further nasal swab, blood test and oral fluid collection in hospital 4 weeks later, in order to assess for immune responses to LAIV.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03735147
Study type	Interventional
Source	Imperial College London
Contact
Status	Completed
Phase	Phase 4
Start date	October 23, 2018
Completion date	April 1, 2019

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03246100` - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates_2nd Trial in Colorado	N/A
Terminated	`NCT01195779` - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children	Phase 2
Completed	`NCT02761551` - Centralized IIS-based Reminder/Recall to Increase Childhood Influenza Vaccination Rates	N/A
Recruiting	`NCT05298800` - Combined Immunization of COVID-19 Inactivated Vaccine With QIV and PPV23	Phase 4
Completed	`NCT02831608` - Study on the Effect of Influenza Vaccination After Heart Attack on Future Cardiovascular Prognosis	Phase 4
Completed	`NCT02560909` - Adjuvanted Influenza Vaccine in Stem Cell Transplant	Phase 4
Withdrawn	`NCT01623232` - MAS-1 Adjuvanted Compared to Unadjuvanted Influenza Vaccines in the Elderly	Phase 1/Phase 2
Completed	`NCT00961337` - Evaluation of a School-based Influenza Vaccination Program	Phase 4
Completed	`NCT00402805` - Improving the Humoral Response to Influenza Vaccine in Lung Transplant Recipients by an Intradermal Strategy	Phase 4
Completed	`NCT00222638` - Influenza Vaccination and Oral Anticoagulant Therapy	Phase 4
Active, not recruiting	`NCT03734237` - A Pragmatic Assessment of Influenza Vaccine Effectiveness in the DoD	Phase 4
Completed	`NCT01013675` - Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly	Phase 2
Completed	`NCT00306995` - Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population	Phase 2
Completed	`NCT01310413` - Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age	Phase 3
Completed	`NCT00449670` - Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults	Phase 3
Completed	`NCT01788228` - Safety and Tolerability Study of GlaxoSmithKline (GSK)1557484A Vaccine in Adults at Occupational Risk for Influenza A (H5N1) Exposure	Phase 3
Completed	`NCT00296270` - Memory for Flu Facts and Myths and Effects on Vaccine Intentions	N/A
Recruiting	`NCT05521763` - Influenza Vaccine Uptake Among Healthcare Workers	N/A
Completed	`NCT00718120` - Immunogenicity and Safety Study of GSK Biologicals' Fluviral® (2008 - 2009 Season) in Adults Over 18 Years	Phase 3
Completed	`NCT00430521` - Safety & Immunogenicity of an Alternative Immunization Schedule of GSK Bio's Pandemic Influenza Vaccine (GSK1119711A)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Assessment of Viral Shedding Week Following Administration of Live Attenuated Influenza Vaccine in Children — FluSHED-2

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms